FDA Approved: VIDAZA — Supplemental Application (Celgene Corporation)

View source ↗

Summary

The FDA approved a Celgene-supplied supplemental application for Vidaza (azacitidine), updating the drug's labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

SUPPL AP for VIDAZA (AZACITIDINE)